04/02/2026
🌍 Today is World Cancer Day — an important moment to highlight the International Osteoporosis Foundation’s recent scientific work addressing bone loss associated with cancer treatments. Over the past year, IOF Bone and Cancer Working Group experts have published the following key papers offering new insights into prevention and management strategies for cancer treatment–related bone loss:
• Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next? 🔗 https://bit.ly/4kkMR2w
• Management of aromatase inhibitor–associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. 🔗 https://bit.ly/4rx6PJJ
• Bone Effects of Anti-Cancer Treatments in 2024. 🔗 https://bit.ly/4atgStn
Professor René Rizzoli, Chair of the IOF Bone and Cancer Working Group, emphasized the importance of addressing this often-overlooked consequence of cancer care:
“While today’s cancer therapies have significantly improved survival, they come with a hidden cost — an increased risk of bone loss and life-altering fragility fractures. For this reason, we strongly advocate for a multidisciplinary approach, bringing together oncologists, endocrinologists, rheumatologists, and general practitioners to ensure early screening and proactive bone-protective strategies for patients at high risk of fracture.”